This content is from: Sponsored Content

GlaxoSmithKline case: Legal form and economic relevance prevail

The Glaxo decision is a positive one for businesses; however, the Supreme Court of Canada (SCC) has sent a clear signal that the transfer pricing policy established for each related party transaction matters and the transfer prices in the case of multiple transactions, such as the licence of a trademark and the supply of both goods and services, will be carefully scrutinised, argue Claire M.C. Kennedy of Bennett Jones and Brad Rolph, president of Transfer Pricing Specialists.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an ITR subscriber? Log in here

Related Content

Instant access to all of our content. Membership Options | 30 Day Trial